Trial success boosts NovoCure

Asaf Danziger credit: PR
Asaf Danziger credit: PR

The company's share price is up over 30% after it announced the results of the trial of its product in treating pancreatic cancer.

NovoCure (Nasdaq: NVCR) announced good results today in its trial of a treatment for pancreatic cancer. The announcement follows the approval granted two months ago for the sale of its treatment for lung cancer. NovoCure’s share price is currently up by more than 30% on Nasdaq, giving the company a market cap of $2.83 billion. The share price is up by 82% for the year to date, after a period of decline.

NovoCure’s trial was conducted on a group of patients with an advanced stage of local pancreatic cancer that could not be surgically removed. The trial group was treated with NovoCure’s product in combination with chemotherapy. The primary endpoint in the trial was the survival rate of patients, and it was clearly met. The proportion of patients still alive in the treated group after two years was 33% higher than in the control group. Median overall survival in the group treated with NovoCure’s product was 16.2 months, which compares with 14.2 months with standard treatment of chemotherapy alone.

Two additional months of life may not sound like much, but that is the median figure, and for some of the patients the gain was greater. NovoCure chief medical officer Nicolas Leupin said, "PANOVA-3 is the first and only Phase 3 trial to demonstrate a statistically significant benefit in overall survival specifically in unresectable, locally advanced pancreatic cancer, and is NovoCure’s third positive Phase 3 clinical trial in the last two years."

On the basis of the trial results, NovoCure will file for regulatory approval of its product, probably next year.

No comparison was carried out in this trial with immunotherapy treatment, a newer method of treatment than chemotherapy approved for use in a small proportion of pancreatic cancer patients. The results of an additional trial, of Novocure’s product in combination with immunotherapy, are expected to be published in 2026.

NovoCure has produced a system for treatment of cancerous cells with focused electric fields - Tumor Treating Fields (TTF) - developed by Prof. Yoram Palti, professor emeritus of physiology and biophysics at the Technion - Israel Institute of Technology, and chief technology officer at NovoCure. The company’s leading product is a helmet for treating glioblastoma (GBM), a form of brain cancer.

In the third quarter of this year, NovoCure had revenue of $166 million, representing 122% growth over the corresponding quarter. In the past few quarters, the company has posted losses because of its high level of investment in development. It has $90 million cash.

Now, the company is aiming at two larger markets. The lung cancer market is ten times larger than the GBM market, and the pancreatic cancer market is five times larger. Novocure is not expected to address the whole market immediately, but rather to expand gradually among patients for whom the treatment is relevant, as it did with brain cancer.

NovoCure recently announced that Asaf Danziger, its CEO for 22 years, almost from the day it was founded, will step down, and will be replaced by the company’s CFO, Ashley Cordova.

Published by Globes, Israel business news - en.globes.co.il - on December 2, 2024.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2024.

Asaf Danziger credit: PR
Asaf Danziger credit: PR
Tel Aviv Stock Exchange share prices rising credit: Tali Bogdanovsky TASE opens sharply higher after Trump U-turn on tariffs

The pause is being interpreted as a climb down after US President Donald Trump admitted he had made the move to calm the markets.

Ashot Ashkelon credit: Ministry of Defense Up 250%, Ashot Ashkelon wins another Defense Ministry order

The Israeli defense company's share price has risen 250% in the past three years since FIMI Opportunity Funds acquired control.

Liad Agmon credit: Eyal Izhar Insight Partners Liad Agmon steps down as managing partner

Serial entrepreneur Agmon has served as a partner at Insight Partners Israel alongside Daniel Aronovitz who set up the Israel office.

Shekels credit: Shutterstock Vladerina32 Shekel slide resumes amid escalating tariff war

The Bank of Israel is not expected to intervene in the forex market despite the sharp depreciation of the shekel.

Nir Zuk credit: Inbal Marmari Palo Alto Networks mulls buying AI security co for $700m

Sources inform "Globes" that on Palo Alto's radar is Protect AI.

President Donald Trump hosts Prime Minister Benjamin Netanyahu credit: Reuters Kevin Mohatt Israeli officials confident on US tariff concessions

Senior Israeli figures believe that concessions could be tied to progress on strategic regional political issues that are important to President Trump.

Phoenix Investment House CEO Avner Hadad  credit: Tommy Harpaz "The market has priced in all the bad things"

Phoenix Investment House CEO Avner Hadad says US markets could continue to fall, but that we are close to interesting territory for patient investors.

Tel Aviv credit: Shutterstock Tel Aviv slips in World's Wealthiest Cities ranking

Tel Aviv's position as one of the world's wealthiest cities took a big knock over the past year as it slipped from 42nd to 48th in investment advisors Henley & Co.'s "World's Wealthiest Cities" Top 50 ranking.

Leviathan platform  credit: Albatross C'ttee seen recommending no cut in gas exports

The Dayan committee on the future of the gas sector estimates that Israel's natural gas reserves will run out in 2045.

Accountant General Yali Rothenberg credit: Rafi Kutz Israel's fiscal deficit continues to narrow

The deficit narrowed in the twelve months to the end of March 2025, for the sixth consecutive month, Ministry of Finance accountant general Yali Rothenberg reported today.

Arkia credit: Arkia Arkia cuts Tel Aviv - New York April fares

Arkia has cut fares at the last minute, a time when prices usually soar even higher, according to the pricing method used in the industry.

Bank of Israel Governor Prof. Amir Yaron credit: Dani Shem Tov Knesset Spokesperson BoI Governor: US tariffs could push up inflation in Israel

Prof. Amir Yaron tells "Globes" that there is a risk that the new tariffs will cause inflation to rise in the US, with a knock-on effect for Israel.

US President Donald Trump and Prime Minister Benjamin Netanyahu April 7, 2025  credit: Avi Ohayon, Government Press Office Netanyahu fails to persuade Trump to remove tariff on Israel

Asked by reporters whether Israel would be exempted from his tariffs policy, US President Donald Trump replied, "Maybe not. Don’t forget we help Israel a lot."

FBI to investigate Nakash Group Israel CEO

The complaint against Avi Hormaro was filed with the FBI offices in Miami, Florida, where many of the group's companies are incorporated, "Globes" has learned.

Bank of Israel credit: Shutterstock Israel's forex reserves fell in March

Israel’s foreign exchange reserves at the end of March 2025 fell to $218.821 billion, a decrease of $1.433 billion from their level at the end of February, the Bank of Israel reports.

Bank of Israel Governor Prof. Amir Yaron credit: GPO BoI keeps rate unchanged, cuts growth forecast

The Bank of Israel is concerned about inflation, the escalation of the war in Gaza, which has raised Israel's risk premium, and the turmoil on global markets set off by the trade war.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018